# Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

> **NCT06561347** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06561347
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561347, "Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06561347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*